Access DB# 73742

RECEIVED
AUG 19
(STIC)

SEARCH REQUEST FORM

Scientific and Technical Informati n Center

Requester's Full Name: Gary Nickol Examiner #: 77581 Date: 8-19-02
Art Unit: 1642 Phone Number 305 7143 Serial Number: 09/853580
Mail Box and Bldg/Room Location: 8D17 (8E12) Results Format Preferred (circle): PAPER DISK E-MAIL

If more than one search is submitted, please prioritize searches in order of need.

****

Please provide a detailed statement of the search topic, and describe as specifically as possible the subject matter to be searched. Include the elected species or structures, keywords, synonyms, acronyms, and registry numbers, and combine with the concept or utility of the invention. Define any terms that may have a special meaning. Give examples or relevant citations, authors, etc, if known. Please attach a copy of the cover sheet, pertinent claims, and abstract.

Title of Invention: See attached

Inventors (please provide full names): " — "

Earliest Priority Filing Date: 9-18-97 (7741)

**For Sequence Searches Only* Please include all pertinent information (parent, child, divisional, or issued patent numbers) along with the appropriate serial number.*

Please search inventors and claims 1, 18, and 21 (see attached)

Thank-you,
Gary Nickol

Point of Contact:
Beverly Sheets
Technical Info Specialist
CM1 1E03 Tel 308-4994

****

STAFF USE ONLY	Type of Search	Vendors and cost where applicable
Searcher: Beverly 4994	NA Sequence (#)	STN ✓
Searcher Phone #:	AA Sequence (#)	Dialog
Searcher Location:	Structure (#)	Questel/Orbit
Date Searcher Picked Up:	Bibliographic	Dr.Link
Date Completed: 08-22-02	Litigation	Lexis/Nexis
Searcher Prep & Review Time: 20	Fulltext	Sequence Systems
Clerical Prep Time:	Patent Family	WWW/Internet
Online Time: 76	Other	Other (specify)

PTO-1590 (8-01)

Nickol
09/853580

FILE 'REGISTRY' ENTERED AT 15:00:52 ON 22 AUG 2002

```
L1            5 S (TWEEN 80 OR TWEEN 20 OR TWEEN 40 OR TWEEN 60 OR "ZWITT
                E TEEPOL HB7/CN 5
L2            1 S E2
                E "ZWITTERGENT 3-12"/CN 5
L3            1 S E3
L4            7 S L1 OR L2 OR L3


L6            3 S (POLOXAMER 401 OR "PLURONIC L62LF" OR "PLURONIC L101" O
                E "PLURONIC L62LF"/CN 5
                E "PLURONIC L 62LF"/CN 5
L7            1 S E3
                E PLURONIC L 101/CN 5
L8            1 S E3
                E PLURONIC L 64/CN 5
L9            1 S E3
                E PEG 1000/CN 5
L10           1 S E3
L11           4 S L6 OR L7 OR L8 OR L9 OR L10


L13           5 S (SQUALANE OR EICOSANE OR TETRATETRACONTANE OR PRISTANE


L16           1 S POLYSORBATE 80/CN


L26          27 S (TYROSINASE OR "N-ACETYLGLUCOSAMINYLTRANSFERASE"? OR ".
                E ".BETA.-CATENIN"/CN 5
L27          34 S ".BETA.-CATENIN"?/CN
                E "MUM-1"/CN 5
                E MAGE/CN 5


                E "CYCLIN DEPENDENT KINASES-4"/CN 5
                E "CYCLIN DEPENDENT KINASES 4"/CN 5
                E "CYCLIN-DEPENDENT KINASE 4"/CN 5
L31           2 S E3-E4

                E TRANSFORMING GROWTH FACTOR/CN
L45           2 S E3-E4
                E "TRANSFORMING GROWTH FACTOR .BETA."/CN
L46         140 S "TRANSFORMING GROWTH FACTOR .BETA."?/CN
L47         142 S L45 OR L46
```

FILE 'HCAPLUS' ENTERED AT 16:01:21 ON 22 AUG 2002

```
L1            5 SEA FILE=REGISTRY ABB=ON  PLU=ON  (TWEEN 80 OR TWEEN 20
                OR TWEEN 40 OR TWEEN 60 OR "ZWITTERGENG 3-12" OR TEEPOL
                HB7 OR SPAN 85)/CN
L2            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "TEEPOL HB 7"/CN
L3            1 SEA FILE=REGISTRY ABB=ON  PLU=ON  "ZWITTERGENT 3-12"/CN
L4            7 SEA FILE=REGISTRY ABB=ON  PLU=ON  L1 OR L2 OR L3
L5        20296 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L4 OR TWEEN(W)(80 OR 20
                OR 40 OR 60) OR ZWITTERGENT 3 12 OR TEEPOL(W)(HB 7 OR
                HB7) OR SPAN 85
L6            3 SEA FILE=REGISTRY ABB=ON  PLU=ON  (POLOXAMER 401 OR
                "PLURONIC L62LF" OR "PLURONIC L101" OR "PLURONIC L64" OR
```

PEG1000 OR TETRONIC 1501 OR TETRONIC 150R1 OR TETRONIC 701 OR TETRONIC 901 OR TETRONIC 1301 OR TETRONIC 130R1)/CN

L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 62LF"/CN
L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 101"/CN
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 64"/CN
L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PEG 1000"/CN
L11 4 SEA FILE=REGISTRY ABB=ON PLU=ON L6 OR L7 OR L8 OR L9 OR L10
L13 5 SEA FILE=REGISTRY ABB=ON PLU=ON (SQUALANE OR EICOSANE OR TETRATETRACONTANE OR PRISTANE OR VEGETABLE OIL)/CN
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON POLYSORBATE 80/CN
L17 2717 SEA FILE=HCAPLUS ABB=ON PLU=ON (L5 OR L16 OR (POLYSORBATE OR POLY SORBATE)(W)80) AND (L11 OR POLOXAMER 401 OR PLURONIC(W)("L62LF" OR "L101" OR "L64" OR L(W)(62LF OR 101 OR 64)) OR PEG1000 OR PEG 1000 OR TETRONIC(W)(1501 OR 150R1 OR 701 OR 901 OR 1301 OR 130R1))
L18 82 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L13 OR SQUALANE OR EICOSANE OR TETRATETRACONTANE OR TETRA(W)(TETRACONTANE OR TETRA CONTANE) OR TETRATETRA CONTANE OR PRISTANE OR VEGETABLE OIL)
L45 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("TRANSFORMING GROWTH FACTOR"/CN OR "TRANSFORMING GROWTH FACTOR (HUMAN MELANOMA A 2058 REDUCED)"/CN)
L46 140 SEA FILE=REGISTRY ABB=ON PLU=ON "TRANSFORMING GROWTH FACTOR .BETA."?/CN
L47 142 SEA FILE=REGISTRY ABB=ON PLU=ON L45 OR L46
~~L48~~ 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (L47 OR TGFB? OR TGF OR TRANSFORM? GROWTH FACTOR)

Claim 18
TGF Beta

L1 5 SEA FILE=REGISTRY ABB=ON PLU=ON (TWEEN 80 OR TWEEN 20 OR TWEEN 40 OR TWEEN 60 OR "ZWITTERGENG 3-12" OR TEEPOL HB7 OR SPAN 85)/CN
L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON "TEEPOL HB 7"/CN
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "ZWITTERGENT 3-12"/CN
L4 7 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3
L5 20296 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 OR TWEEN(W)(80 OR 20 OR 40 OR 60) OR ZWITTERGENT 3 12 OR TEEPOL(W)(HB 7 OR HB7) OR SPAN 85
L6 3 SEA FILE=REGISTRY ABB=ON PLU=ON (POLOXAMER 401 OR "PLURONIC L62LF" OR "PLURONIC L101" OR "PLURONIC L64" OR PEG1000 OR TETRONIC 1501 OR TETRONIC 150R1 OR TETRONIC 701 OR TETRONIC 901 OR TETRONIC 1301 OR TETRONIC 130R1)/CN
L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 62LF"/CN
L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 101"/CN
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 64"/CN
L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PEG 1000"/CN
L11 4 SEA FILE=REGISTRY ABB=ON PLU=ON L6 OR L7 OR L8 OR L9 OR L10
L13 5 SEA FILE=REGISTRY ABB=ON PLU=ON (SQUALANE OR EICOSANE OR TETRATETRACONTANE OR PRISTANE OR VEGETABLE OIL)/CN
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON POLYSORBATE 80/CN
L17 2717 SEA FILE=HCAPLUS ABB=ON PLU=ON (L5 OR L16 OR (POLYSORBATE OR POLY SORBATE)(W)80) AND (L11 OR POLOXAMER 401 OR PLURONIC(W)("L62LF" OR "L101" OR "L64" OR L(W)(62LF OR

101 OR 64)) OR PEG1000 OR PEG 1000 OR TETRONIC(W)(1501 OR 150R1 OR 701 OR 901 OR 1301 OR 130R1))

L18 82 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L13 OR SQUALANE OR EICOSANE OR TETRATETRACONTANE OR TETRA(W)(TETRACONTANE OR TETRA CONTANE) OR TETRATETRA CONTANE OR PRISTANE OR VEGETABLE OIL)

L23 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (ANTIGEN OR GP100 OR GP(W)(75 OR 100) OR MART(W)(1 OR I) OR MARTI OR MART1 OR GP75 OR TYRSINASE OR MELANOMA(W)(PROTEOGLYCAN OR PROTEO GLYCAN) OR MAGE OR BAGE OR GAGE OR RAGE OR ACETYGLUCOSAMIN? OR ACETYL(W)(GLUCOSAMIN? OR GLUCOS AMIN?))

L24 4 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (CATENIN OR MUM1 OR MUMI OR MUM(W)(1 OR I) OR CYCLIN(1W)KINASE OR RAS OR BCR OR P53 OR P185 OR P(W)(53 OR 185) OR HER2 OR HER 2 OR EPIDERM?(1W)FACTOR OR MUCIN OR PAPILLOMAVIR? OR PAPILLOMA VIR? OR EBNA OR PSA OR PROSTAT?(1W)MEMBRANE OR PCTA#)

L25 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (IMMUNOGLOBULIN OR IMMUNO GLOBULIN OR IG OR T(1W)RECEPTOR)(W)IDIOTYP?

L26 27 SEA FILE=REGISTRY ABB=ON PLU=ON (TYROSINASE OR "N-ACETYLGLUCOSAMINYLTRANSFERASE"? OR ".BETA.-CATENIN" OR "MUM-1")/CN

L27 34 SEA FILE=REGISTRY ABB=ON PLU=ON ".BETA.-CATENIN"?/CN

L31 2 SEA FILE=REGISTRY ABB=ON PLU=ON ("CYCLIN-DEPENDENT KINASE 4"/CN OR "CYCLIN-DEPENDENT KINASE 4 (RAT CLONE RCDK4)"/CN)

L32 1 SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (L26 OR L27 OR L31 OR TYROSINASE OR ACETYLGLUCOS? OR ACETYL GLUCOS? OR TCR)

L33 13 SEA FILE=HCAPLUS ABB=ON PLU=ON L23 OR L24 OR L25 OR L32

claim 21 Antigens

L49 L3 L48 OR L33

L49 ANSWER 1 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1999:215575 HCAPLUS
DOCUMENT NUMBER: 130:247033
TITLE: Synergistic composition and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis
INVENTOR(S): Hanna, Nabil; Braslawsky, Gary R.; Hariharan, Kandasamy
PATENT ASSIGNEE(S): Idec Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 41 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9913912	A1	19990325	WO 1998-US18495	19980917

W: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL,

TJ, TM, TR, TT, UA, UG, UZ, VN, YU, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM
RW: GH, GM, KE, LS, MW, SD, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG

ZA 9808461	A	19990330	ZA 1998-8461	19980916
CA 2303178	AA	19990325	CA 1998-2303178	19980917
AU 9895658	A1	19990405	AU 1998-95658	19980917
AU 742216	B2	20011220		
EP 1015031	A1	20000705	EP 1998-949313	19980917
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, FI				
JP 2001516727	T2	20011002	JP 2000-511527	19980917
NO 2000001413	A	20000518	NO 2000-1413	20000317
US 2001018054	A1	20010830	US 2001-853580	20010514
US 2001019715	A1	20010906	US 2001-853581	20010514
PRIORITY APPLN. INFO.:			US 1997-933359 A	19970918
			WO 1998-US18495 W	19980917

AB A method for treating neoplastic or cancerous growths and for treating cancer patients to restore or boost hematopoiesis comprises administration of a combination of a cytotoxic T-lymphocyte (CTL)-inducing compn. and .gtoreq.1 agent capable of neutralizing or down-regulating the activity of tumor-secreted immunosuppressive factors such as **TGF**-.beta. and IL-10, sep. or in combination. The CTL inducer is typically a vaccine for enhancing tumor immunity which lacks an immunostimulating peptide component and is formulated as a stable oil-in-water emulsion contg. a micelle-forming agent. The combination produces a synergistic enhancement of the CTL response. Since **TGF**-.beta. neg. regulates and/or inhibits the growth of hematopoietic cells, the treatment can improve hematopoiesis during cancer therapy. Thus, mice bearing progressively growing ovalbumin-expressing EG7 tumors showed a delay in tumor growth after treatment with 30 .mu.g ovalbumin in Provax adjuvant and 50 .mu.g anti-**TGF**-.beta. antibodies.

IT **111-01-3, Squalane 112-95-8, Eicosane 1921-70-6, Pristane 7098-22-8, Tetratetracontane 9005-64-5, Tween 20 9005-65-6, Tween 80 9005-66-7, Tween 40 9005-67-8, Tween 60 14933-08-5, Zwittergent 3-12 25322-68-3**, PEG **26266-58-0, Span 85 106392-12-5, Poloxamer 401 107397-59-1, Tetronic 150R1 110617-70-4, Tetronic 130R1 134092-79-8, Teepol HB 7**
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(in vaccine adjuvant; synergistic compn. and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis)

IT **147014-97-9, Cyclin**-dependent **kinase** 4
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(mutants, vaccine contg.; synergistic compn. and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis)

IT **9002-10-2, Tyrosinase 83588-90-3, N-Acetylglucosaminyltransferase** V
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(vaccine contg.; synergistic compn. and methods for treating neoplastic or cancerous growths and for restoring or boosting hematopoiesis)

REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L49 ANSWER 2 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1998:58829 HCAPLUS
DOCUMENT NUMBER: 128:127067
TITLE: Induction of cytotoxic T lymphocyte responses
INVENTOR(S): Raychaudhuri, Syamal; Rastetter, William H.
PATENT ASSIGNEE(S): IDEC Pharmaceuticals Corp., USA
SOURCE: U.S., 27 pp., Cont.-in-part of U.S. Ser. No. 919,787.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5709860	A	19980120	US 1994-351001	19941207
US 5585103	A	19961217	US 1992-919787	19920724
US 5695770	A	19971209	US 1995-472311	19950607
CA 2204738	AA	19960613	CA 1995-2204738	19951129
WO 9617863	A1	19960613	WO 1995-US15433	19951129
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
AU 9644104	A1	19960626	AU 1996-44104	19951129
AU 699044	B2	19981119		
EP 801656	A1	19971022	EP 1995-942921	19951129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
BR 9509872	A	19971125	BR 1995-9872	19951129
CN 1175260	A	19980304	CN 1995-197570	19951129
JP 10510264	T2	19981006	JP 1995-517641	19951129
NO 9702521	A	19970806	NO 1997-2521	19970603
FI 9702431	A	19970606	FI 1997-2431	19970606
LT 4308	B	19980325	LT 1997-115	19970704
LV 11866	B	19980120	LV 1997-132	19970707
US 6197311	B1	20010306	US 1998-24220	19980217
US 2002039582	A1	20020404	US 2000-740003	20001220

PRIORITY APPLN. INFO.:
US 1991-735069 B2 19910725
US 1992-919787 A2 19920724
US 1994-351001 A1 19941207
US 1995-476674 B1 19950607

WO 1995-US15433 W 19951129
US 1997-919787 B2 19970829
US 1998-24220 A1 19980217

AB Methods and compns. useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the **antigen** to which the CTL response is desired and providing an **antigen** formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This **antigen** formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

IT **111-01-3, Squalane 112-95-8, Eicosane 1921-70-6, Pristane 7098-22-8, Tetratetracontane 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 14933-08-5, Zwittergent 3-12 25322-68-3, PEG1000 26266-58-0, Span 85 106392-12-5, Poloxamer 401 107397-59-1, Tetronic 150R1 110617-70-4, Tetronic 1501 134092-79-8, Teepol HB7**
RL: AGR (Agricultural use); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(emulsion formulation contg. **antigen** and stabilizer and micelle-forming agent and biodegradable oil for induction of cytotoxic T lymphocyte responses for infection and cancer therapy)

L49 ANSWER 3 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1997:9866 HCAPLUS
DOCUMENT NUMBER: 126:135602
TITLE: Induction of cytotoxic T-lymphocyte responses
INVENTOR(S): Raychaudhuri, Syamal; Rastetter, William H.
PATENT ASSIGNEE(S): Idec Pharmaceutical Corporation, USA
SOURCE: U.S., 21 pp., Cont.-in-part of U.S. Ser. No. 735,069,abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5585103	A	19961217	US 1992-919787	19920724
CA 2113750	AA	19930204	CA 1992-2113720	19920704
HU 69784	A2	19950928	HU 1994-202	19920724
HU 220295	B	20011128		
IL 102639	A1	19970318	IL 1992-102639	19920724
AT 166578	E	19980615	AT 1992-917479	19920724
ES 2117052	T3	19980801	ES 1992-917479	19920724
CZ 288048	B6	20010411	CZ 1994-150	19920724
ZA 9205614	A	19930420	ZA 1992-5614	19920727

US 5709860	A	19980120	US 1994-351001		19941207
US 6270769	B1	20010807	US 1995-449728		19950524
US 5695770	A	19971209	US 1995-472311		19950607
US 6197311	B1	20010306	US 1998-24220		19980217
PRIORITY APPLN. INFO.:			US 1991-735069	B2	19910725
			CS 1994-150	A	19920724
			US 1992-919787	A	19920724
			US 1994-351001	A1	19941207
			US 1995-476674	B1	19950607

AB Methods and compns. useful for inducing a cytotoxic T lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the **antigen** to which the CTL response is desired and providing an **antigen** formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This **antigen** formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

IT **111-01-3, Squalane 112-95-8, Eicosane 1921-70-6, Pristane 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 14933-08-5, Zwittergent 3-12 25322-68-3 26266-58-0, Span 85 106392-12-5, Pluronic L64 110617-70-4, Tetronic 1301 134092-79-8, Teepol hb7**
RL: PEP (Physical, engineering or chemical process); THU (Therapeutic use); BIOL (Biological study); PROC (Process); USES (Uses)
(formulations for induction of cytotoxic T-lymphocyte responses)

L49 ANSWER 4 OF 13 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1996:536217 HCAPLUS
DOCUMENT NUMBER:	125:192942
TITLE:	Cytokines and antibody subclass associated with protective immunity against blood-stage malaria in mice vaccinated with the C terminus of merozoite surface protein 1 plus a novel adjuvant
AUTHOR(S):	De Souza, J. Brian; Ling, Irene T.; Ogun, Sola A.; Holder, Anthony A.; Playfair, John H. L.
CORPORATE SOURCE:	Dep. of Immunology, Univ. College London Medical Sch., London, W1P 9PG, UK
SOURCE:	Infection and Immunity (1996), 64(9), 3532-3536 CODEN: INFIBR; ISSN: 0019-9567
PUBLISHER:	American Society for Microbiology
DOCUMENT TYPE:	Journal
LANGUAGE:	English

AB A blood-stage malaria **antigen** comprising the C terminus of merozoite surface protein 1 fused to glutathione S-transferase, combined with an adjuvant formulation contg. **squalane**, **Tween 80**, and pluronic L121 (AF), administered s.c. protected mice against death from a lethal Plasmodium yoelii infection. The protection induced by this **antigen**

-adjuvant combination was compared with that induced by the **antigen** plus saponin in terms of survival from the lethal infection and clearance of parasitemia. The levels of gamma interferon and interleukin-4 in spleens were measured as indicators of Th1 and Th2 cell activation, and antibody classes and subclasses were detd. by immunofluorescence. With a 10-.mu.g dose of **antigen** and AF as adjuvant, all mice recovered, but with saponin as the adjuvant, there were only a few survivors. With 30 .mu.g of **antigen** plus AF, the peak parasitemias were 10-fold lower than those with 10 .mu.g; with saponin, survival was slightly improved. The levels of both gamma interferon and interleukin-4 rose more rapidly and to higher levels with AF as the adjuvant than with saponin, and the same was true for IgG1, IgG2a, and IgG2b subclasses. Thus, in terms of both cytokine prodn. and antibody levels, AF is a more potent adjuvant for a malaria vaccine than is saponin.

IT **111-01-3, Squalane 9005-65-6, Tween 80 106392-12-5,** Pluronic L121
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); BIOL (Biological study)
(effect of vaccination with the C terminus of merozoite surface protein 1 plus a novel adjuvant on cytokines and antibody levels in mice)

L49 ANSWER 5 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:483722 HCAPLUS
DOCUMENT NUMBER: 125:140546
TITLE: Induction of cytotoxic T-lymphocyte responses
INVENTOR(S): Raychaudhuri, Syamal; Rastetter, William H.
PATENT ASSIGNEE(S): Idec Pharmaceuticals Corporation, USA
SOURCE: PCT Int. Appl., 72 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9617863	A1	19960613	WO 1995-US15433	19951129
W: AL, AM, AT, AU, BB, BG, BR, BY, CA, CH, CN, CZ, DE, DK, EE, ES, FI, GB, GE, HU, IS, JP, KE, KG, KP, KR, KZ, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK				
RW: KE, LS, MW, SD, SZ, UG, AT, BE, CH, DE, DK, ES, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, NE, SN, TD, TG				
US 5709860	A	19980120	US 1994-351001	19941207
AU 9644104	A1	19960626	AU 1996-44104	19951129
AU 699044	B2	19981119		
EP 801656	A1	19971022	EP 1995-942921	19951129
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE				
BR 9509872	A	19971125	BR 1995-9872	19951129
JP 10510264	T2	19981006	JP 1995-517641	19951129
NO 9702521	A	19970806	NO 1997-2521	19970603
FI 9702431	A	19970606	FI 1997-2431	19970606

PRIORITY APPLN. INFO.: US 1994-351001 A 19941207

US 1991-735069 B2 19910725
US 1992-919787 A2 19920724
WO 1995-US15433 W 19951129

AB Methods and compns. useful for inducing a cytotoxic T-lymphocyte response (CTL) in a human or domesticated or agriculturally important animal. The method includes the steps of providing the **antigen** to which the CTL response is desired and providing an **antigen** formulation which comprises, consists, or consists essentially of two or more of a stabilizing detergent, a micelle-forming agent, and an oil. This **antigen** formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. This formulation is provided as a stable oil-in-water emulsion.

IT **111-01-3, Squalane 112-95-8, Eicosane 1921-70-6, Pristane 7098-22-8, Tetratetracontane 9005-64-5, Tween 20 9005-65-6, Polysorbate 80 9005-66-7, Tween 40 9005-67-8, Tween 60 14933-08-5, Zwittergent 3-12 25322-68-3 26266-58-0, Span 85 106392-12-5, Poloxamer 401 107397-59-1, Tetronic 150R1 110617-70-4, Tetronic 1301 134092-79-8, Teepol HB7**
RL: MOA (Modifier or additive use); USES (Uses)
(compn. contg. **antigen** and detergent and micelle-forming agent and oil for induction of cytotoxic T lymphocyte)

L49 ANSWER 6 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1996:2559 HCAPLUS
DOCUMENT NUMBER: 124:97440
TITLE: A novel adjuvant for use with a blood-stage malaria vaccine
AUTHOR(S): De Souza, J. B.; Playfair, J. H. L.
CORPORATE SOURCE: Medical School, University College London, London, W1P 9PG, UK
SOURCE: Vaccine (1995), 13(14), 1316-19
CODEN: VACCDE; ISSN: 0264-410X
PUBLISHER: Elsevier
DOCUMENT TYPE: Journal
LANGUAGE: English

AB An effective vaccine delivery system has been developed for vaccination against a blood-stage malaria infection in mice. S.c. vaccination with a semi-purified asexual blood-stage malaria **antigen** combined with an adjuvant formulation contg. **squalane, Tween 80,** and pluronic L121 (AF) protected mice infected with a lethal Plasmodium yoelii infection against death and greatly reduced the severity and duration of parasitemia. The adjuvant and the route of immunization are both clin. acceptable, thereby making this an attractive delivery system for a human malaria vaccine. Protective immunity appeared to be assocd. with an enhancement of both Th1 and Th2 subset cytokines.

IT **111-01-3, Squalane 9005-65-6, Tween 80 106392-12-5,** Pluronic L121

RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(novel adjuvant for use with blood-stage malaria vaccine)

L49 ANSWER 7 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:874953 HCAPLUS
DOCUMENT NUMBER: 123:296634
TITLE: Convertible microemulsion formulations
INVENTOR(S): Owen, Albert J.; Yiv, Seang H.; Sarkahian, Ani B.
PATENT ASSIGNEE(S): Ibah, Inc., USA
SOURCE: U.S., 32 pp. Cont.-in-part of U.S. Ser. No. 841,931, abandoned.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 5444041	A	19950822	US 1992-885202	19920520
CA 2108266	AA	19921020	CA 1992-2108266	19920415
AT 183099	E	19990815	AT 1992-911731	19920415
IL 101613	A1	19980222	IL 1992-101613	19920416
CN 1066183	A	19921118	CN 1992-102762	19920418
US 5633226	A	19970527	US 1995-425787	19950420
US 5646109	A	19970708	US 1995-425475	19950420
US 5688761	A	19971118	US 1995-406862	19950608

PRIORITY APPLN. INFO.:

US 1991-687691	B2	19910419
US 1992-837347	B2	19920214
US 1992-841931	B2	19920225
WO 1992-US3086	A	19920415
US 1992-885202	A1	19920520
US 1992-963326	B2	19921016
WO 1993-US9933	W	19931015

AB There is provided a water-in-oil (w/o) microemulsion which readily converts to an oil-in-water (o/w) emulsion by the addn. of aq. fluid to the w/o microemulsion, whereby any water-sol. biol.-active material in the aq. phase is released for absorption by the body. The w/o microemulsion is particularly useful for storing proteins and the like for long periods of time at room temp. and above until they are ready for use, at which time the addn. of aq. fluid converts the microemulsion to an o/w emulsion and releases the protein. For example, a w/o microemulsion base for the delivery of His-D-Trp-Ala-Trp-D-Phe-Lys-NH2 was formulated contg. Captex 200 68.3, Capmul MCM 8.3, Centrophase 31 (lecithins) 1.6, Cremophor EL 16.5, and water 5.3%.

IT **9005-65-6, Tween 80 25322-68-3**
, Polyethylene glycol
RL: THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(convertible microemulsion formulations for biol. active proteins)

L49 ANSWER 8 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1995:755189 HCAPLUS
DOCUMENT NUMBER: 123:141186
TITLE: The induction of cytotoxic T cells and tumor regression by soluble **antigen**

formulation
AUTHOR(S): Hariharan, Kandasamy; Braslawsky, Gary; Black, Amelia; Raychaudhuri, Syamal; Hanna, Nabil
CORPORATE SOURCE: IDEC Pharmaceuticals, San Diego, CA, 92121, USA
SOURCE: Cancer Res. (1995), 55(16), 3486-9
CODEN: CNREA8; ISSN: 0008-5472
DOCUMENT TYPE: Journal
LANGUAGE: English

AB CTLs specific for tumor **antigens** play a major role in the immunity against cancer. We have shown that class I-restricted CTLs can be induced by injecting sol. **antigens** mixed in an **antigen** formulation (AF) that consists of **squalane**, **Tween 80**, and Pluronic L121 (S. Raychaudhuri et al., 1992). In this study, using ovalbumin and the ovalbumin-expressing transfectoma (EG7) as a tumor model system, we examd. the in vivo antitumor effect of **antigen**-AF mixt. Vaccination of mice with ovalbumin in AF 2 or 3 days after EG7 tumor challenge showed significant inhibition of tumor growth compared to mice vaccinated with ovalbumin in alum or in saline. Depletion of CD8+ cells at the time of immunization completely abrogated the AF-induced tumor protection, indicating that CD8+ T cells are the major effectors in tumor protection in vivo. Depletion of CD4+ cells led to a marginal loss of tumor protection, which may be the result of inhibition of ovalbumin-specific CTL response due to the lack of T-helper activity. Our results demonstrate that AF can be used in subunit vaccines to stimulate CTLs and tumor regression in vivo.

IT **111-01-3, Squalane 9005-65-6, Tween 80 106392-12-5,** Pluronic L121
RL: BAC (Biological activity or effector, except adverse); THU (Therapeutic use); BIOL (Biological study); USES (Uses)
(cytotoxic T cells and tumor regression induction by sol. **antigen** formulation contg.)

L49 ANSWER 9 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:415331 HCAPLUS
DOCUMENT NUMBER: 119:15331
TITLE: Convertible microemulsion formulations
INVENTOR(S): Owen, Albert J.; Yiv, Seang H.; Sarkahian, Ani B.
PATENT ASSIGNEE(S): Affinity Biotech, Inc., USA
SOURCE: PCT Int. Appl., 102 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9218147	A1	19921029	WO 1992-US3086	19920415
W: AU, BB, BG, BR, CA, CS, FI, HU, JP, KP, KR, LK, MG, MN, MW, NO, PL, RO, RU, SD				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, MC, ML, MR, NL, SE, SN, TD, TG				
CA 2108266	AA	19921020	CA 1992-2108266	19920415
AU 9218966	A1	19921117	AU 1992-18966	19920415
AU 668509	B2	19960509		

EP 580778	A1	19940202	EP 1992-911731	19920415
EP 580778	B1	19990811		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE				
JP 06507172	T2	19940811	JP 1992-511743	19920415
AT 183099	E	19990815	AT 1992-911731	19920415
ES 2136620	T3	19991201	ES 1992-911731	19920415
IL 101613	A1	19980222	IL 1992-101613	19920416
CN 1066183	A	19921118	CN 1992-102762	19920418
US 5633226	A	19970527	US 1995-425787	19950420
US 5646109	A	19970708	US 1995-425475	19950420

PRIORITY APPLN. INFO.:
US 1991-687691 A 19910419
US 1992-837347 A 19920214
US 1992-841931 A 19920225
WO 1992-US3086 A 19920415
US 1992-885202 A1 19920520

AB A phase-reversible (convertible) water-in-oil (w/o) microemulsion comprises up to .apprx.60 vol.% of internally dispersed aq. phase contg. a drug (e.g. protein, peptide, immunogen), .apprx.5-99 vol.% of an oily phase (e.g. diesters of propylene glycol), and .apprx.1-70 vol.% of a surfactant with HLB value of 7-14. Addn. of aq. soln. converts the microemulsion to an o/w emulsion which releases the protein. Thus, Captex 200 870.0, polyoxyethylene (50) sorbitol hexaoleate 50.0, Cremophor EL 50.0, and saline soln. 30.0.mu.L were mixed at 25.degree. to provide a clear w/o microemulsion. Water was then added to the total compn. in the ratio of 4:1 (vol./vol.) to convert the microemulsion to the o/w emulsion.

IT **9005-65-6, Tween 80 25322-68-3**
, Polyethylene glycol
RL: BIOL (Biological study)
(microemulsions contg., convertible water-oil)

L49 ANSWER 10 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1993:219835 HCAPLUS
DOCUMENT NUMBER: 118:219835
TITLE: Emulsion compositions and methods for induction of cytotoxic T-lymphocyte (CTL) responses
INVENTOR(S): Raychaudhuri, Syamal; Rastetter, William H.
PATENT ASSIGNEE(S): Idec Pharmaceuticals Corp., USA
SOURCE: PCT Int. Appl., 56 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 4
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9301831	A1	19930204	WO 1992-US6193	19920724
W: AT, AU, BB, BG, BR, CA, CH, CS, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MG, MN, MW, NL, NO, PL, RO, RU, SD, SE, US				
RW: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LU, MC, NL, SE, BF, BJ, CF, CG, CI, CM, GA, GN, ML, MR, SN, TD, TG				
CA 2113750	AA	19930204	CA 1992-2113720	19920704
AU 9224338	A1	19930223	AU 1992-24338	19920724
AU 666127	B2	19960201		
EP 596032	A1	19940511	EP 1992-917479	19920724
EP 596032	B1	19980527		

R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, MC, NL, SE

JP 06509344	T2	19941020	JP 1992-503071		19920724
BR 9206310	A	19950425	BR 1992-6310		19920724
HU 69784	A2	19950928	HU 1994-202		19920724
HU 220295	B	20011128			
IL 102639	A1	19970318	IL 1992-102639		19920724
AT 166578	E	19980615	AT 1992-917479		19920724
ES 2117052	T3	19980801	ES 1992-917479		19920724
RU 2129439	C1	19990427	RU 1994-38046		19920724
RO 116459	B1	20010228	RO 1994-94		19920724
ZA 9205614	A	19930420	ZA 1992-5614		19920727
NO 9400218	A	19940325	NO 1994-218		19940121
FI 9400335	A	19940324	FI 1994-335		19940124
FI 2001001187	A	20010605	FI 2001-1187		20010605
PRIORITY APPLN. INFO.:			US 1991-735069	A2	19910725
			WO 1992-US6193	A	19920724

AB Compns. and methods are disclosed for inducing a CTL response in a human or domesticated or agriculturally important animal. The method includes the steps of providing the **antigen** to which the CTL response is desired and providing an **antigen** formulation which comprises, consists, or consists essentially of .gtoreq.2 of a stabilizing detergent, a micelle-forming agent, and an oil. The **antigen** formulation is preferably lacking in an immunostimulating peptide component, or has sufficiently low levels of such a component that the desired CTL response is not diminished. The formulation is provided as a stable oil-in-water emulsion. The components of the emulsion are chosen such that the emulsion will remain in an emulsion state for .ltoreq.1 mo, preferably >1 yr, without phase sepn. Thus, mice were injected with ovalbumin with an **antigen** formulation (AF) of squalene-Pluronic L121-**Tween 80**, and spleen cells from the immunized mice were tested against EG7-ova cells (an ovalbumin-expressing EL4 transfectant). A significant transfectant-specific CTL response was shown. Ovalbumin-AF-primed effector cells also lysed untransfected EL4 cells coated with ovalbumin fragment 253-276, but did not lyse EL4 cells coated with a myelin basic protein fragment. The CTL effectors were shown to be CD8+ T-cells. The effect of substitutions in the three-component AF system was detd., as was the effect of two-component systems (e.g. squalene-**Tween 80**). Use of the AF in producing class I-restricted CTL priming by sol. gp120 of human immunodeficiency virus is also described, as are AF components necessary for antibody prodn.

IT **111-01-3 9005-65-6, Tween 80**
106392-12-5
RL: BIOL (Biological study)
(**antigen**-emulsion compn. with, cytotoxic T-lymphocyte induction in relation to)

L49 ANSWER 11 OF 13 HCAPLUS COPYRIGHT 2002 ACS

ACCESSION NUMBER:	1992:172259 HCAPLUS
DOCUMENT NUMBER:	116:172259
TITLE:	Adjuvants and vaccines containing Pluronics and lipopolysaccharides
INVENTOR(S):	Hunter, Robert L.; Takayama, Kuni K.
PATENT ASSIGNEE(S):	Emory University, USA
SOURCE:	PCT Int. Appl., 87 pp. CODEN: PIXXD2

DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 9200101	A1	19920109	WO 1991-US4716	19910627
W: AT, AU, BB, BG, BR, CA, CH, DE, DK, ES, FI, GB, HU, JP, KP, KR, LK, LU, MC, MG, MW, NL, NO, RO, SD, SE, SU				
RW: AT, BE, BF, BJ, CF, CG, CH, CI, CM, DE, DK, ES, FR, GA, GB, GN, GR, IT, LU, ML, MR, NL, SE, SN, TD, TG				
CA 2086097	AA	19911228	CA 1991-2086097	19910627
AU 9182861	A1	19920123	AU 1991-82861	19910627
AU 655593	B2	19950105		
CN 1060027	A	19920408	CN 1991-105280	19910627
EP 536302	A1	19930414	EP 1991-913213	19910627
EP 536302	B1	19970827		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE				
BR 9106601	A	19930420	BR 1991-6601	19910627
JP 05507498	T2	19931028	JP 1991-512657	19910627
JP 08032639	B4	19960329		
AT 157259	E	19970915	AT 1991-913213	19910627
ES 2104712	T3	19971016	ES 1991-913213	19910627
US 5554372	A	19960910	US 1995-420333	19950411

PRIORITY APPLN. INFO.:

US 1990-544831	19900627
US 1991-716807	19910621
US 1986-909964	19860922
US 1987-75187	19870716
US 1988-208335	19880617
US 1989-341315	19890421
US 1989-449086	19891208
WO 1991-US4716	19910627
US 1993-133760	19931007

AB An improved immunol. adjuvant comprises a surface-active copolymer HO(C2H4O)b(C3H6O)a(C2H4O)bH (I), wherein the mol. wt. of the hydrophobe (C3H6O) is 4500-9000 and the percentage of hydrophile (C2H4O) is 3-15 wt.%, and/or a nontoxic lipopolysaccharide from Rhodopseudomonas. This adjuvant intensifies the immuńe response to an **antigen** or a vaccine and may also change the predominant isotype of antibody produced. Thus, an oil-in-water emulsion was prepd. contg. 2% **squalane** in phosphate-buffered saline (pH 7.4) contg. trinitrophenyl ovalbumin (**antigen**), **Tween 80** (emulsifier), I (adjuvant), and [(C3H6O)b(C2H4O)a]2NCH2CH2N[(C2H4O)a(C3H6O)b]2 (a = 5, b = 32) (II). The combination of I and II gave a synergistic adjuvant effect.

IT **106392-12-5**, Pluronic
RL: BIOL (Biological study)
(vaccine adjuvant contg.)

L49 ANSWER 12 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1989:560235 HCAPLUS
DOCUMENT NUMBER: 111:160235
TITLE: Vaccines comprising polyoxypropylene-polyoxyethylene block polymer based adjuvants
INVENTOR(S): Allison, Anthony C.; Byars, Noelene E.
PATENT ASSIGNEE(S): Syntex (U.S.A.), Inc., USA

SOURCE: U.S., 10 pp. Cont.-in-part of U.S. 4,606,918.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 2
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 4772466	A	19880920	US 1985-703791	19850221
US 4606918	A	19860819	US 1983-525190	19830822
DK 8404006	A	19850223	DK 1984-4006	19840821
DK 167173	B1	19930913		
AU 8432251	A1	19850228	AU 1984-32251	19840821
AU 578907	B2	19881110		
JP 60105630	A2	19850611	JP 1984-174861	19840821
JP 06017314	B4	19940309		
ZA 8406504	A	19860326	ZA 1984-6504	19840821
IL 72740	A1	19880229	IL 1984-72740	19840821
CA 1236017	A1	19880503	CA 1984-461465	19840821
US 4933179	A	19900612	US 1985-703837	19850221
US 4770874	A	19880913	US 1986-859665	19860505
JP 06065097	A2	19940308	JP 1993-203231	19930817
JP 2557603	B2	19961127		

PRIORITY APPLN. INFO.: US 1983-525190 19830822
OTHER SOURCE(S): MARPAT 111:160235

AB A vaccine contains an immunolog. effective amt. of an **antigen**, a multiphase-forming amt. of a polyoxypropylene-polyoxyethylene block polymer, a glycol ether-based surfactant, an immunopotentiating amt. of an immunostimulating glycopeptide, and buffered isoosmotic saline in a quantity sufficient to make vol. Feline leukemia virus vaccine was prepd. from an adjuvant comprising a soln. A 84.5, soln. B 0.5, **squalane** 10.0, and Pluronic L-121 5.0%, wherein the soln. A contained NaCl 80.0, KCl 2.0, KH2PO4 2.0, Na2HPO4.7H2O 21.6g, **Tween 80** 40.0 mL, and distd. water to 10,000 mL, and the soln. B contained N-acetylmuranyl-L-threonyl-D-isoglutamine 0.6g and the soln. A. 50.0 mL. Two doses of the vaccine were administered to cats 5 and 2 wk prior to an infection with feline leukemia virus by the nasal route and blood samples were tested for viral **antigens** in the blood by indirect fluorescent antibody techniques and for p27 **antigens** by ELISA; the use of the above adjuvant significantly increased the protection of the cats when compared to an Al hydroxide gel/Quil A adjuvant.

IT **9005-65-6, Tween 80**
RL: BIOL (Biological study)
(vaccine adjuvants contg. polyoxypropylene-polyoxyethylene block copolymer and immunostimulating glycopeptides and)

IT **106392-12-5**, Pluronic L-121
RL: BIOL (Biological study)
(vaccine adjuvants contg. surfactants and immunostimulating glycopeptides and)

L49 ANSWER 13 OF 13 HCAPLUS COPYRIGHT 2002 ACS
ACCESSION NUMBER: 1988:498633 HCAPLUS
DOCUMENT NUMBER: 109:98633
TITLE: The development of an adjuvant formulation that elicits cell-mediated and humoral immune

responses to virus subunit and other **antigens**

AUTHOR(S): Allison, Anthony C.; Byars, Neolene E.

CORPORATE SOURCE: Inst. Biol. Sci., Syntex Res., Palo Alto, CA, 94304, USA

SOURCE: Prog. Leukocyte Biol. (1987), 6(Immunopharmacol. Infect. Dis.), 191-201
CODEN: PLBIE5; ISSN: 0884-6790

DOCUMENT TYPE: Journal

LANGUAGE: English

AB N-Acetylmuramyl-L-threonyl-p-isoglutamine ([Thr1]MDP) was selected as an adjuvant with sepn. of adjuvant activity from side effects such as pyrogenicity, capacity to induce uveitis and arthritis, and to increase resistance to infections. Pluronic L121, **squalane** and **Tween 80** were used with the adjuvant to produce a 2-phase system with **antigens** concd. at the interphase. This formulation is esp. useful for vaccines based on recombinant DNA technol.

IT **9005-65-6, Tween 80 106392-12-5**
, Pluronic L121
RL: BIOL (Biological study)
(immune adjuvant formulation contg. muramyldipeptide deriv. and, for vaccines)

[redacted] BIOSIS, EMBASE, WPIDS, CONFSCI, SCISEARCH, JICST-EPLUS, JAPIO, CANCERLIT' ENTERED AT 16:04:55 ON 22 AUG 2002)

L1 5 SEA FILE=REGISTRY ABB=ON PLU=ON (TWEEN 80 OR TWEEN 20 OR TWEEN 40 OR TWEEN 60 OR "ZWITTERGENG 3-12" OR TEEPOL HB7 OR SPAN 85)/CN
L2 1 SEA FILE=REGISTRY ABB=ON PLU=ON "TEEPOL HB 7"/CN
L3 1 SEA FILE=REGISTRY ABB=ON PLU=ON "ZWITTERGENT 3-12"/CN
L4 7 SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3
L5 20296 SEA FILE=HCAPLUS ABB=ON PLU=ON L4 OR TWEEN(W)(80 OR 20 OR 40 OR 60) OR ZWITTERGENT 3 12 OR TEEPOL(W)(HB 7 OR HB7) OR SPAN 85
L6 3 SEA FILE=REGISTRY ABB=ON PLU=ON (POLOXAMER 401 OR "PLURONIC L62LF" OR "PLURONIC L101" OR "PLURONIC L64" OR PEG1000 OR TETRONIC 1501 OR TETRONIC 150R1 OR TETRONIC 701 OR TETRONIC 901 OR TETRONIC 1301 OR TETRONIC 130R1)/CN
L7 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 62LF"/CN
L8 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 101"/CN
L9 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 64"/CN
L10 1 SEA FILE=REGISTRY ABB=ON PLU=ON "PEG 1000"/CN
L11 4 SEA FILE=REGISTRY ABB=ON PLU=ON L6 OR L7 OR L8 OR L9 OR L10
L13 5 SEA FILE=REGISTRY ABB=ON PLU=ON (SQUALANE OR EICOSANE OR TETRATETRACONTANE OR PRISTANE OR VEGETABLE OIL)/CN
L16 1 SEA FILE=REGISTRY ABB=ON PLU=ON POLYSORBATE 80/CN
L17 2717 SEA FILE=HCAPLUS ABB=ON PLU=ON (L5 OR L16 OR (POLYSORBATE OR POLY SORBATE)(W)80) AND (L11 OR POLOXAMER 401 OR PLURONIC(W)("L62LF" OR "L101" OR "L64" OR L(W)(62LF OR 101 OR 64)) OR PEG1000 OR PEG 1000 OR TETRONIC(W)(1501 OR 150R1 OR 701 OR 901 OR 1301 OR 130R1))
L18 82 SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L13 OR SQUALANE OR EICOSANE OR TETRATETRACONTANE OR TETRA(W)(TETRACONTANE OR TETRA CONTANE) OR TETRATETRA CONTANE OR PRISTANE OR VEGETABLE OIL)

L45	2	SEA FILE=REGISTRY ABB=ON PLU=ON ("TRANSFORMING GROWTH FACTOR"/CN OR "TRANSFORMING GROWTH FACTOR (HUMAN MELANOMA A 2058 REDUCED)"/CN)
L46	140	SEA FILE=REGISTRY ABB=ON PLU=ON "TRANSFORMING GROWTH FACTOR .BETA."?/CN
L47	142	SEA FILE=REGISTRY ABB=ON PLU=ON L45 OR L46
L48	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (L47 OR TGFB? OR TGF OR TRANSFORM? GROWTH FACTOR)
~~L50~~	1	SEA L48
L1	5	SEA FILE=REGISTRY ABB=ON PLU=ON (TWEEN 80 OR TWEEN 20 OR TWEEN 40 OR TWEEN 60 OR "ZWITTERGENG 3-12" OR TEEPOL HB7 OR SPAN 85)/CN
L2	1	SEA FILE=REGISTRY ABB=ON PLU=ON "TEEPOL HB 7"/CN
L3	1	SEA FILE=REGISTRY ABB=ON PLU=ON "ZWITTERGENT 3-12"/CN
L4	7	SEA FILE=REGISTRY ABB=ON PLU=ON L1 OR L2 OR L3
L5	20296	SEA FILE=HCAPLUS ABB=ON PLU=ON L4 OR TWEEN(W)(80 OR 20 OR 40 OR 60) OR ZWITTERGENT 3 12 OR TEEPOL(W)(HB 7 OR HB7) OR SPAN 85
L6	3	SEA FILE=REGISTRY ABB=ON PLU=ON (POLOXAMER 401 OR "PLURONIC L62LF" OR "PLURONIC L101" OR "PLURONIC L64" OR PEG1000 OR TETRONIC 1501 OR TETRONIC 150R1 OR TETRONIC 701 OR TETRONIC 901 OR TETRONIC 1301 OR TETRONIC 130R1)/CN
L7	1	SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 62LF"/CN
L8	1	SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 101"/CN
L9	1	SEA FILE=REGISTRY ABB=ON PLU=ON "PLURONIC L 64"/CN
L10	1	SEA FILE=REGISTRY ABB=ON PLU=ON "PEG 1000"/CN
L11	4	SEA FILE=REGISTRY ABB=ON PLU=ON L6 OR L7 OR L8 OR L9 OR L10
L13	5	SEA FILE=REGISTRY ABB=ON PLU=ON (SQUALANE OR EICOSANE OR TETRATETRACONTANE OR PRISTANE OR VEGETABLE OIL)/CN
L16	1	SEA FILE=REGISTRY ABB=ON PLU=ON POLYSORBATE 80/CN
L17	2717	SEA FILE=HCAPLUS ABB=ON PLU=ON (L5 OR L16 OR (POLYSORBATE OR POLY SORBATE)(W)80) AND (L11 OR POLOXAMER 401 OR PLURONIC(W)("L62LF" OR "L101" OR "L64" OR L(W)(62LF OR 101 OR 64)) OR PEG1000 OR PEG 1000 OR TETRONIC(W)(1501 OR 150R1 OR 701 OR 901 OR 1301 OR 130R1))
L18	82	SEA FILE=HCAPLUS ABB=ON PLU=ON L17 AND (L13 OR SQUALANE OR EICOSANE OR TETRATETRACONTANE OR TETRA(W)(TETRACONTANE OR TETRA CONTANE) OR TETRATETRA CONTANE OR PRISTANE OR VEGETABLE OIL)
L23	13	SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (ANTIGEN OR GP100 OR GP(W)(75 OR 100) OR MART(W)(1 OR I) OR MARTI OR MART1 OR GP75 OR TYRSINASE OR MELANOMA(W)(PROTEOGLYCAN OR PROTEO GLYCAN) OR MAGE OR BAGE OR GAGE OR RAGE OR ACETYGLUCOSAMIN? OR ACETYL(W)(GLUCOSAMIN? OR GLUCOS AMIN?))
L24	4	SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (CATENIN OR MUM1 OR MUMI OR MUM(W)(1 OR I) OR CYCLIN(1W)KINASE OR RAS OR BCR OR P53 OR P185 OR P(W)(53 OR 185) OR HER2 OR HER 2 OR EPIDERM?(1W)FACTOR OR MUCIN OR PAPILLOMAVIR? OR PAPILLOMA VIR? OR EBNA OR PSA OR PROSTAT?(1W)MEMBRANE OR PCTA#)
L25	1	SEA FILE=HCAPLUS ABB=ON PLU=ON L18 AND (IMMUNOGLOBULIN OR IMMUNO GLOBULIN OR IG OR T(1W)RECEPTOR)(W)IDIOTYP?

```
L26          27 SEA FILE=REGISTRY ABB=ON  PLU=ON  (TYROSINASE OR
                "N-ACETYLGLUCOSAMINYLTRANSFERASE"? OR ".BETA.-CATENIN"
                OR "MUM-1")/CN
L27          34 SEA FILE=REGISTRY ABB=ON  PLU=ON  ".BETA.-CATENIN"?/CN
L31           2 SEA FILE=REGISTRY ABB=ON  PLU=ON  ("CYCLIN-DEPENDENT
                KINASE 4"/CN OR "CYCLIN-DEPENDENT KINASE 4 (RAT CLONE
                RCDK4)"/CN)
L32           1 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L18 AND (L26 OR L27 OR
                L31 OR TYROSINASE OR ACETYLGLUCOS? OR ACETYL GLUCOS? OR
                TCR)
L33          13 SEA FILE=HCAPLUS ABB=ON  PLU=ON  L23 OR L24 OR L25 OR
                L32
L36           4 SEA L33


=> s l50 or l36
L51           4 L50 OR L36

=> dup rem l51
PROCESSING COMPLETED FOR L51
L52           4 DUP REM L51 (0 DUPLICATES REMOVED)

L52  ANSWER 1 OF 4  WPIDS (C) 2002 THOMSON DERWENT
ACCESSION NUMBER:     1999-357351 [30]   WPIDS
DOC. NO. CPI:         C1999-105653
TITLE:                New immunogenic compositions for treating cancer or
                      virus or parasite infection.
DERWENT CLASS:        A96 B04 D16
INVENTOR(S):          BRASLAWSKY, G R; HANNA, N; HARIHARAN, K; HARIHARA,
                      K
PATENT ASSIGNEE(S):   (IDEC-N) IDEC PHARM CORP
COUNTRY COUNT:        84
PATENT INFORMATION:

     PATENT NO   KIND DATE     WEEK      LA   PG
     ---------------------------------------------
     WO 9913912    A1 19990325 (199930)* EN   41
        RW: AT BE CH CY DE DK EA ES FI FR GB GH GM GR IE IT KE LS LU MC
            MW NL OA PT SD SE SZ UG ZW
         W: AL AM AT AU AZ BA BB BG BR BY CA CH CN CU CZ DE DK EE ES FI
            GB GE GH GM HR HU ID IL IS JP KE KG KP KR KZ LC LK LR LS LT
            LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL
            TJ TM TR TT UA UG UZ VN YU ZW
     ZA 9808461    A  19990630 (199931)       36
     AU 9895658    A  19990405 (199933)
     EP 1015031    A1 20000705 (200035)  EN
         R: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE
     NO 2000001413 A  20000518 (200035)
     CN 1279616    A  20010110 (200128)
     US 2001018054 A1 20010830 (200151)
     US 2001019715 A1 20010906 (200154)
     KR 2001024109 A  20010326 (200161)
     JP 2001516727 W  20011002 (200172)       32
     AU 742216     B  20011220 (200208)

APPLICATION DETAILS:

     PATENT NO   KIND                 APPLICATION      DATE
```

WO 9913912	A1		WO 1998-US18495	19980917
ZA 9808461	A		ZA 1998-8461	19980916
AU 9895658	A		AU 1998-95658	19980917
EP 1015031	A1		EP 1998-949313	19980917
			WO 1998-US18495	19980917
NO 2000001413	A		WO 1998-US18495	19980917
			NO 2000-1413	20000317
CN 1279616	A		CN 1998-811280	19980917
US 2001018054	A1	Cont of	US 1997-933359	19970918
			US 2001-853580	20010514
US 2001019715	A1	Div ex	US 1997-933359	19970918
			US 2001-853581	20010514
KR 2001024109	A		KR 2000-702864	20000317
JP 2001516727	W		WO 1998-US18495	19980917
			JP 2000-511527	19980917
AU 742216	B		AU 1998-95658	19980917

FILING DETAILS:

PATENT NO	KIND		PATENT NO
AU 9895658	A	Based on	WO 9913912
EP 1015031	A1	Based on	WO 9913912
JP 2001516727	W	Based on	WO 9913912
AU 742216	B	Previous Publ.	AU 9895658
		Based on	WO 9913912

PRIORITY APPLN. INFO: US 1997-933359 19970918; US 2001-853580 20010514; US 2001-853581 20010514

AN 1999-357351 [30] WPIDS

AB WO 9913912 A UPAB: 19990802

NOVELTY - New immunogenic compositions for treating cancer or virus or parasite infection comprise a combination of **antigen** formulation and an agent capable of neutralizing or down-regulating immunosuppressive factors.

DETAILED DESCRIPTION - A composition (A) comprises:

(a) an admixture comprising a cancer, viral or parasitic **antigen** expressed by cancer, virally or parasitic infected cells and a microfluidized **antigen** formulation (MAF) (formulated as a stable oil-in-water emulsion), the **antigen** formulation comprising:

(i) a stabilizing detergent;

(ii) a micelle-forming agent; and

(iii) a biodegradable and biocompatible oil; and

(b) at least one agent which is capable of neutralizing or down-regulating the activity of immunosuppressive factors.

INDEPENDENT CLAIMS are also included for the following:

(1) a method of treatment which includes the induction of a cytotoxic T-lymphocyte (CTL) response where the improvement comprises:

(a) the administration of an adjuvant which induces a CTL response; and

(b) the administration of an antagonist of an immunosuppressive factor, where the administration of adjuvant and antagonist is effected sequentially or concurrently, and in any order;

(2) a method of restoring or boosting hematopoiesis comprising administering to a patient:

(a) an admixture as in (A) (a) which is administered to the patient to induce a CTL response in the patient which is specific for the viral or cancer **antigen** contained in the admixture; and

(b) at least one agent which is capable of neutralizing or down regulating the activity of tumor and host secreted immunosuppressive factors, where the admixture and the agent are administered separately or in combination, and in any order;

(3) a composition comprising an admixture as in (A) (a) and one or more **transforming growth factor** (**TGF**) beta antagonists;

(4) treatment of neoplastic or cancerous growths, comprising:

(a) administration of an admixture comprising a cancer or tumor **antigen** expressed by the cancer cells and a MAF (described above); and

(b) administration of at least one agent which is capable of neutralizing or down-regulating the activity of tumors and host secreted immunosuppressive factors. The admixture is administered in an amount sufficient to induce a cytotoxic T-lymphocyte response in the patient which is specific for the cancer or tumor **antigen** contained in the admixture.

ACTIVITY - Antitumor; Antiviral; Antiparasitic.

MECHANISM OF ACTION - Induction of a cytotoxic T-lymphocyte response.

USE - The methods can be used for restoring or boosting hematopoiesis (claimed). They can be used for treating cancers, e.g. breast cancer, brain cancer, cervical cancer, leukemia, lymphoma, prostate cancer, skin cancer, bladder cancer, kidney cancer, myeloma, colorectal cancer, or endometrial cancer, viral infections e.g. **papillomavirus**, hepatitis, herpes, cytomegalovirus, respiratory syncytial virus or HIV, or parasitic infection, e.g. malaria (claimed). The agent which is capable of neutralizing or down-regulating the activity of immunosuppressive factors enhances the efficacy of tumor/viral vaccines.

ADVANTAGE - The combinations of the **antigen** compositions and antagonists of immunosuppressive agents results in a synergistic enhancement of CTL response, thereby resulting in enhanced therapeutic response against targeted **antigen** -expressing cells.

Dwg.0/4

L52 ANSWER 2 OF 4 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1997:539321 BIOSIS
DOCUMENT NUMBER: PREV199799838524
TITLE: **Antigen** formulation for recombinant cancer vaccines.
AUTHOR(S): Hanna, Nabil; Black, Amelia; Hariharan, Kandasamy
CORPORATE SOURCE: IDEC Pharm. Corp., 11011 Torreyana Rd., San Diego, CA 92121 USA
SOURCE: International Journal of Oncology, (1997) Vol. 11, No. SUPPL., pp. 924.
Meeting Info.: 2nd World Congress on Advances in Oncology Athens, Greece October 16-18, 1997
ISSN: 1019-6439.
DOCUMENT TYPE: Conference; Abstract
LANGUAGE: English

L52 ANSWER 3 OF 4 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.

ACCESSION NUMBER: 1995:440683 BIOSIS
DOCUMENT NUMBER: PREV199598454983
TITLE: The Induction of Cytotoxic T Cells and Tumor Regression by Soluble **antigen** Formulation.
AUTHOR(S): Hariharan, Kandasamy (1); Braslawsky, Gary; Black, Amelia; Raychaudhuri, Syamal; Hanna, Nabil
CORPORATE SOURCE: (1) IDEC Pharmaceuticals Corporation, 11011 Torreyana Road, San Diego, CA 92121 USA
SOURCE: Cancer Research, (1995) Vol. 55, No. 16, pp. 3486-3489.
ISSN: 0008-5472.
DOCUMENT TYPE: Article
LANGUAGE: English

AB CTLs specific for tumor **antigens** play a major role in the immunity against cancer. We have shown that class I-restricted CTLs can be induced by injecting soluble **antigens** mixed in an **antigen** formulation (AF) that consists of **squalane**, **Tween 80**, and Pluronic L121 (S. Raychaudhuri et al., Proc. Natl. Acad. Sci. USA, 89: 8308-8312, 1992). In this study, using ovalbumin and the ovalbumin-expressing transfectoma (EG7) as a tumor model system, we examined the in vivo antitumor effect of **antigen**-AF mixture. Vaccination of mice with ovalbumin in AF 2 or 3 days after EG7 tumor challenge showed significant inhibition of tumor growth compared to mice vaccinated with ovalbumin in alum or in saline. Depletion of CD8+ cells at the time of immunization completely abrogated the AF-induced tumor protection, indicating that CD8+ T cells are the major effectors in tumor protection in vivo. Depletion of CD4+ cells led to a marginal loss of tumor protection, which may be the result of inhibition of ovalbumin-specific CTL response due to the lack of T-helper activity. Our results demonstrate that AF can be used in subunit vaccines to stimulate CTLs and tumor regression in vivo.

L52 ANSWER 4 OF 4 BIOSIS COPYRIGHT 2002 BIOLOGICAL ABSTRACTS INC.
ACCESSION NUMBER: 1987:462907 BIOSIS
DOCUMENT NUMBER: BA84:108347
TITLE: ADJUVANT FORMULATION FOR USE IN VACCINES TO ELICIT BOTH CELL-MEDIATED AND HUMORAL IMMUNITY.
AUTHOR(S): BYARS N E; ALLISON A C
CORPORATE SOURCE: INST. BIOL. SCI., SYNTEX RES., 3401 HILLVIEW AVE., PALO ALTO, CALIF. 94304.
SOURCE: VACCINE, (1987) 5 (3), 223-228.
CODEN: VACCDE. ISSN: 0264-410X.
FILE SEGMENT: BA; OLD
LANGUAGE: English

AB Adjuvant formulations which elicit both humoral and cell-mediated immunity will be required for vaccines based on peptides, viral and bacterial subunits and genetically engineered **antigens**. This report describes an adjuvant formulation which increases both cell-mediated and humoral immunity and is free of significant side effects encountered with other adjuvants or vehicles. The components include the threonyl analogue of muramyl dipeptide. **Tween 80**, Pluronic L121 and **squalane**. This formulation was found to be effective with several **antigens**, in several species, including rodents, cats and monkeys. These results suggest that the formulation will be useful for both human and veterinary vaccines.

09/853580

FILE 'HOME' ENTERED AT 16:16:23 ON 22 AUG 2002

Searcher : Shears 308-4994